Avadel Pharmaceuticals is a drug manufacturers-specialty & generic business based in the US. Avadel Pharmaceuticals shares (AVDL) are listed on the NASDAQ and all prices are listed in US Dollars. Avadel Pharmaceuticals employs 41 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $13.84 |
|---|---|
| 52-week range | $1.05 - $15.82 |
| 50-day moving average | $10.90 |
| 200-day moving average | $8.02 |
| Wall St. target price | $16.45 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.37 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.84 from 2023-05-26
| 1 week (2023-05-19) | -2.95% |
|---|---|
| 1 month (2023-04-28) | 32.06% |
| 3 months (2023-02-28) | 39.10% |
| 6 months (2022-11-28) | 74.09% |
| 1 year (2022-05-27) | 453.60% |
|---|---|
| 2 years (2021-05-28) | 79.97% |
| 3 years (2020-05-28) | 73.87% |
| 5 years (2018-05-25) | 105.04% |
Valuing Avadel Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Avadel Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Avadel Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.07. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Avadel Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Gross profit TTM | $16.6 million |
|---|---|
| Return on assets TTM | -31.32% |
| Return on equity TTM | -481.49% |
| Profit margin | 0% |
| Book value | $-0.34 |
| Market capitalisation | $1.1 billion |
TTM: trailing 12 months
We're not expecting Avadel Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Avadel Pharmaceuticals's shares have ranged in value from as little as $1.05 up to $15.82. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Avadel Pharmaceuticals's is 1.4339. This would suggest that Avadel Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland. .
Access remote advice, planning and portfolio management from this established financial services company.
Steps to owning and managing ET, with 24-hour and historical pricing before you buy.
Steps to owning and managing UEC, with 24-hour and historical pricing before you buy.
Steps to owning and managing GROY, with 24-hour and historical pricing before you buy.
The best trading apps come with low fees and are easy to use.
Here’s what happens to your securities if your brokerage fails, and how your assets are protected by SIPC and FDIC.
Learn about buying physical gold, plus stocks and ETFs, to learn how you can add gold exposure to your portfolio.
Several ETFs have exposure to Silicon Valley Bank, but it appears minimal.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
The 16th largest US bank has collapsed, but its impact on your portfolio could be limited depending on what you own.